Cell Reports (Jul 2023)

FOXA2 controls the anti-oxidant response in FH-deficient cells

  • Connor Rogerson,
  • Marco Sciacovelli,
  • Lucas A. Maddalena,
  • Andromachi Pouikli,
  • Marc Segarra-Mondejar,
  • Lorea Valcarcel-Jimenez,
  • Christina Schmidt,
  • Ming Yang,
  • Elena Ivanova,
  • Joshua Kent,
  • Ariane Mora,
  • Danya Cheeseman,
  • Jason S. Carroll,
  • Gavin Kelsey,
  • Christian Frezza

Journal volume & issue
Vol. 42, no. 7
p. 112751

Abstract

Read online

Summary: Hereditary leiomyomatosis and renal cell cancer (HLRCC) is a cancer syndrome caused by inactivating germline mutations in fumarate hydratase (FH) and subsequent accumulation of fumarate. Fumarate accumulation leads to profound epigenetic changes and the activation of an anti-oxidant response via nuclear translocation of the transcription factor NRF2. The extent to which chromatin remodeling shapes this anti-oxidant response is currently unknown. Here, we explored the effects of FH loss on the chromatin landscape to identify transcription factor networks involved in the remodeled chromatin landscape of FH-deficient cells. We identify FOXA2 as a key transcription factor that regulates anti-oxidant response genes and subsequent metabolic rewiring cooperating without direct interaction with the anti-oxidant regulator NRF2. The identification of FOXA2 as an anti-oxidant regulator provides additional insights into the molecular mechanisms behind cell responses to fumarate accumulation and potentially provides further avenues for therapeutic intervention for HLRCC.

Keywords